OPGx-LCA5 is under clinical development by Opus Genetics and currently in Phase II for Leber Congenital Amaurosis (LCA). According to GlobalData, Phase II drugs for Leber Congenital Amaurosis (LCA) have a 60% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how OPGx-LCA5’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

OPGx-LCA5 overview

OPGx-LCA5 is under development for the treatment of Leber congenital amaurosis (LCA). The therapeutic candidate comprises Adeno associated virus 8(AAV 8) delivering LCA5 gene, which encodes the lebercilin protein. It is administered through unilateral subretinal injection.

Opus Genetics overview

Opus Genetics (Opus Genetic) is a patient-first, science driven gene therapy company tackling manufacturing obstacles standing in the way of treatments for ultra-rare blinding conditions. Opus Genetics is headquartered in Raleigh, North Carolina, the US.

For a complete picture of OPGx-LCA5’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.